BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 33226988)

  • 1. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model.
    Pavel STI; Yetiskin H; Kalkan A; Ozdarendeli A
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008834. PubMed ID: 33226988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside-Modified mRNA Vaccines Protect IFNAR
    Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
    J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.
    Garrison AR; Shoemaker CJ; Golden JW; Fitzpatrick CJ; Suschak JJ; Richards MJ; Badger CV; Six CM; Martin JD; Hannaman D; Zivcec M; Bergeron E; Koehler JW; Schmaljohn CS
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005908. PubMed ID: 28922426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
    Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
    J Virol; 2017 May; 91(10):. PubMed ID: 28250124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models.
    Aligholipour Farzani T; Földes K; Hanifehnezhad A; Yener Ilce B; Bilge Dagalp S; Amirzadeh Khiabani N; Ergünay K; Alkan F; Karaoglu T; Bodur H; Ozkul A
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30857305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.
    Dowall SD; Buttigieg KR; Findlay-Wilson SJ; Rayner E; Pearson G; Miloszewska A; Graham VA; Carroll MW; Hewson R
    Hum Vaccin Immunother; 2016; 12(2):519-27. PubMed ID: 26309231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virus.
    Canakoglu N; Berber E; Ertek M; Yoruk MD; Tonbak S; Bolat Y; Aktas M; Kalkan A; Ozdarendeli A
    Virol J; 2013 Jan; 10():6. PubMed ID: 23282186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.
    Hawman DW; Meade-White K; Haddock E; Habib R; Scott D; Thomas T; Rosenke R; Feldmann H
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31292241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge.
    Zivcec M; Safronetz D; Scott DP; Robertson S; Feldmann H
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006628. PubMed ID: 30011277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever.
    Rodriguez SE; Cross RW; Fenton KA; Bente DA; Mire CE; Geisbert TW
    Sci Rep; 2019 May; 9(1):7755. PubMed ID: 31123310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-Delivery Effect of CD24 on the Immunogenicity and Lethal Challenge Protection of a DNA Vector Expressing Nucleocapsid Protein of Crimean Congo Hemorrhagic Fever Virus.
    Aligholipour Farzani T; Hanifehnezhad A; Földes K; Ergünay K; Yilmaz E; Hashim Mohamed Ali H; Ozkul A
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30658445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain.
    Papa A; Papadimitriou E; Christova I
    Scand J Infect Dis; 2011 Mar; 43(3):225-9. PubMed ID: 21142621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine.
    Spengler JR; Welch SR; Scholte FEM; Coleman-McCray JD; Harmon JR; Nichol ST; Bergeron É; Spiropoulou CF
    Antiviral Res; 2019 Oct; 170():104573. PubMed ID: 31377243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine.
    Mousavi-Jazi M; Karlberg H; Papa A; Christova I; Mirazimi A
    Vaccine; 2012 Sep; 30(44):6225-9. PubMed ID: 22902680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice.
    Lindquist ME; Zeng X; Altamura LA; Daye SP; Delp KL; Blancett C; Coffin KM; Koehler JW; Coyne S; Shoemaker CJ; Garrison AR; Golden JW
    J Virol; 2018 Nov; 92(21):. PubMed ID: 30111561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.
    Kortekaas J; Vloet RP; McAuley AJ; Shen X; Bosch BJ; de Vries L; Moormann RJ; Bente DA
    Vector Borne Zoonotic Dis; 2015 Dec; 15(12):759-64. PubMed ID: 26684523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.
    Zivcec M; Guerrero LIW; Albariño CG; Bergeron É; Nichol ST; Spiropoulou CF
    Antiviral Res; 2017 Oct; 146():112-120. PubMed ID: 28842265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of two serological methods for detecting IgG and neutralizing antibodies against Crimean-Congo hemorrhagic fever virus glycoprotein.
    Wang Q; Wang S; Shi Z; Li Z; Zhao Y; Feng N; Wang T; Yan F; Xia X
    Front Cell Infect Microbiol; 2024; 14():1341332. PubMed ID: 38746783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Novel Multi-Epitope Vaccine Against Crimean-Congo Hemorrhagic Fever Virus: An Integrated Reverse Vaccinology, Vaccine Informatics and Biophysics Approach.
    Tahir Ul Qamar M; Ismail S; Ahmad S; Mirza MU; Abbasi SW; Ashfaq UA; Chen LL
    Front Immunol; 2021; 12():669812. PubMed ID: 34220816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular (ticks) and serological (humans) study of Crimean-Congo hemorrhagic fever virus in the Iberian Peninsula, 2013-2015.
    Palomar AM; Portillo A; Santibáñez S; García-Álvarez L; Muñoz-Sanz A; Márquez FJ; Romero L; Eiros JM; Oteo JA
    Enferm Infecc Microbiol Clin; 2017; 35(6):344-347. PubMed ID: 28291670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.